Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Egfr Tyrosine Kinase Inhibitor”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Post-approval studies (Phase 4)Not Yet RecruitingNCT07469488
What this trial is testing

A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-Mutated Advanced NSCLC Receiving Amivantamab-Based Regimens

Who this might be right for
NSCLC (Advanced Non-small Cell Lung Cancer)VTE (Venous Thromboembolism)Rash Due to Epidermal Growth Factor Receptor Inhibitors+1 more
Shanghai Pulmonary Hospital, Shanghai, China 122
Testing effectiveness (Phase 2)Study completedNCT04239846
What this trial is testing

Prophylactic Treatment of Skin Rash Associated With EGFR Inhibitor Therapy

Who this might be right for
EGFR Inhibitor-Induced Skin Rash
TWi Biotechnology, Inc. 74
Testing effectiveness (Phase 2)Study completedNCT02759835
What this trial is testing

Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib

Who this might be right for
Lung AdenocarcinomaLung Neoplasms
National Cancer Institute (NCI) 37
Testing effectiveness (Phase 2)Ended earlyNCT02454842
What this trial is testing

Study for Treatment With TH-4000 (Tarloxotinib) in Epidermal Growth Factor Receptor (EGFR) Mutant, T790M-negative Non-small Cell Lung Cancer (NSCLC) Patients

Who this might be right for
Non-small Cell Lung CancerNSCLCNon-squamous NSCLC
Rain Oncology Inc 21
Large-scale testing (Phase 3)Study completedNCT02454933
What this trial is testing

Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours

Who this might be right for
Locally Advanced or Metastatic EGFR T790M+ NSCLC
AstraZeneca 29
Testing effectiveness (Phase 2)Study completedNCT02646020
What this trial is testing

Aprepitant vs. Desloratadine in EGFR-TKIs Related Pruritus Treatment

Who this might be right for
Non-small Cell Lung Cancer
Sun Yat-sen University 138
Testing effectiveness (Phase 2)Study completedNCT00633750
What this trial is testing

Erlotinib in Treating Patients With Breast Cancer That Can Be Removed by Surgery

Who this might be right for
Breast Cancer
Vanderbilt-Ingram Cancer Center 50
Not applicableStudy completedNCT02169349
What this trial is testing

Molecular Diagnosis on Circulating Tumor DNA of Non-Small Cell Lung Cancer

Who this might be right for
Stage IIIb and IV Non Small Cell Lung Cancer
Rennes University Hospital 100
Testing effectiveness (Phase 2)Ended earlyNCT01205685
What this trial is testing

Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer

Who this might be right for
Hormone-sensitive Metastatic Breast Cancer
Vanderbilt-Ingram Cancer Center 11
Early research (Phase 1)Study completedNCT00656786
What this trial is testing

Safety, Tolerability and Systemic Absorption of Menadione Topical Lotion for Epidermal-Growth-Factor-Receptor (EGFR) Inhibitor-Associated Rash

Who this might be right for
EGFR Inhibitor-associated Rash
Spectrum Pharmaceuticals, Inc 18
Early research (Phase 1)Study completedNCT06001671
What this trial is testing

Antitumor Activity and Safety of BEBT-109, a Novel EGFR Inhibitor, in Previously Treated NSCLC

Who this might be right for
NSCLC
Hunan Province Tumor Hospital 23
Testing effectiveness (Phase 2)Looking for participantsNCT07699328
What this trial is testing

VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer

Who this might be right for
EGFR-Mutant Non-Small Cell Lung Cancer
Voronoi, Inc 315
Early research (Phase 1)Ended earlyNCT01288430
What this trial is testing

DS-2248 in Participants With Advanced Solid Tumors

Who this might be right for
Solid TumorsNon-small Cell Lung Carcinoma
Daiichi Sankyo 60
Testing effectiveness (Phase 2)UnknownNCT03797391
What this trial is testing

A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors

Who this might be right for
NeoplasmsNeoplasm MetastasisNon-Small-Cell Lung Cancer
Shanghai EpimAb Biotherapeutics Co., Ltd. 186
Not applicableWithdrawnNCT03519958
What this trial is testing

Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong Kong

Who this might be right for
Non-small Cell Lung Cancer
AstraZeneca
Testing effectiveness (Phase 2)Looking for participantsNCT06818058
What this trial is testing

TAR-0520 Gel in EGFR Inhibitor-induced Folliculitis

Who this might be right for
EGFR Inhibitor-associated Rash
Tarian Pharma 60
Early research (Phase 1)Study completedNCT00551850
What this trial is testing

A Safety Study of an Oral EGFR Inhibitor, AV-412, Administered Three Times Weekly in Advanced Solid Tumor Patients

Who this might be right for
Advanced CancerRefractory Cancer
AVEO Pharmaceuticals, Inc. 37
Early research (Phase 1)Study completedNCT02228369
What this trial is testing

Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer

Who this might be right for
EGFR Mutation Positive Advanced Non Small Cell Lung Cancer
AstraZeneca 108
Testing effectiveness (Phase 2)Study completedNCT00720304
What this trial is testing

Erlotinib, Docetaxel, and Radiation Therapy in Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck

Who this might be right for
Head and Neck Cancer
Case Comprehensive Cancer Center 43
Early research (Phase 1)Study completedNCT02113813
What this trial is testing

A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations

Who this might be right for
Non-Small-Cell Lung Cancer (NSCLC)Epidermal Growth Factor Receptor Mutations
Astellas Pharma Global Development, Inc. 133
Next Page